Company intelligence / Profile preview

HepaSense

Bermuda

Ownership: Private
Development stage: Other

Overview

HepaSense Ltd. was a biopharmaceutical joint venture established in 2000 by Isis Pharmaceuticals (now Ionis Pharmaceuticals) and Elan Corporation to develop antisense drugs for chronic Hepatitis C. The company's primary focus was the clinical development of ISIS 14803, a first-generation antisense inhibitor of the Hepatitis C virus (HCV). Following Elan's restructuring and withdrawal from the partnership in 2002, Isis reacquired full rights to the lead candidate. Isis eventually acquired Elan's remaining interest in 2004 and dissolved the HepaSense entity in 2005.

Therapeutic areas: Infectious Diseases
Modalities: Antisense oligonucleotide
Industry: Biotech

Partnerships

Elan Corporation

Beyond the preview

Go deeper on HepaSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HepaSense.

Explore the full profile